Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review.
Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review.
复制标题
DOI：
10.3390/ijms222313070
复制
发表时间：
2021-12-02
影响因子：
5.6
通讯作者：
Dakanalis A
中科院分区：
文献类型：
--
作者：
Caldiroli A;Capuzzi E;Tagliabue I;Capellazzi M;Marcatili M;Mucci F;Colmegna F;Clerici M;Buoli M;Dakanalis A
难治性抑郁症(TRD)与不良预后相关，但关于哪种化合物代表抗抑郁药(AD)的最佳药理强化策略，文献中缺乏共识。在目前的综述中，我们确定了现有的关于药物对TRD中AD的增强作用的文献。在主要的精神病学数据库(PubMed，ISI Web of Knowledge，ousInfo)中进行研究。仅收录英文原文，主题为TRD的药理学增强，并给出TRD的准确定义。阿立哌唑和锂是研究最多的分子，阿立哌唑提供了最有力的疗效证据。此外，奥氮平、奎硫平、卡里普秦、利培酮和齐拉西酮也显示出阳性结果，但程度较小。在现实世界的实践中，布雷克哌唑和鼻腔内注射埃斯氯胺酮还需要进一步研究。静注氯胺酮在短期内表现出可预防的AD效应。根据有限的现有数据，无法准确估计辅助ADS、抗癫痫药物、精神刺激剂、普拉克索、罗匹尼罗、乙酰水杨酸、甲氧苯丙酮、利血平、睾酮、T3/T4、纳曲酮、SAME和锌的疗效。关于拉莫三嗪和吲哚洛尔的研究报告结果为阴性。根据我们的结果，阿立哌唑和锂可能被临床医生认为是治疗TRD的潜在有效的强化策略，尽管关于锂的数据有些争议。关于其他分子，我们无法得出可靠的结论。需要进一步的对照比较研究，在强化治疗的设计、剂量和持续时间方面进行标准化，以得出明确的结论。
Treatment resistant depression (TRD) is associated with poor outcomes, but a consensus is lacking in the literature regarding which compound represents the best pharmacological augmentation strategy to antidepressants (AD). In the present review, we identify the available literature regarding the pharmacological augmentation to AD in TRD. Research in the main psychiatric databases was performed (PubMed, ISI Web of Knowledge, PsychInfo). Only original articles in English with the main topic being pharmacological augmentation in TRD and presenting a precise definition of TRD were included. Aripiprazole and lithium were the most investigated molecules, and aripiprazole presented the strongest evidence of efficacy. Moreover, olanzapine, quetiapine, cariprazine, risperidone, and ziprasidone showed positive results but to a lesser extent. Brexpiprazole and intranasal esketamine need further study in real-world practice. Intravenous ketamine presented an evincible AD effect in the short-term. The efficacy of adjunctive ADs, antiepileptic drugs, psychostimulants, pramipexole, ropinirole, acetyl-salicylic acid, metyrapone, reserpine, testosterone, T3/T4, naltrexone, SAMe, and zinc cannot be precisely estimated in light of the limited available data. Studies on lamotrigine and pindolol reported negative results. According to our results, aripiprazole and lithium may be considered by clinicians as potential effective augmentative strategies in TRD, although the data regarding lithium are somewhat controversial. Reliable conclusions about the other molecules cannot be drawn. Further controlled comparative studies, standardized in terms of design, doses, and duration of the augmentative treatments, are needed to formulate definitive conclusions.
登录
查看更多内容
影响因子：
2.9
作者：
Altamura, Alfredo Carlo;Dell'Osso, Bernardo;Mundo, Emanuela
通讯作者：
Mundo, Emanuela
DOI：
10.1176/appi.focus.16407
发表时间：
2018-10-01
期刊：
Focus (American Psychiatric Publishing)
影响因子：
--
作者：
Cipriani, Andrea;Furukawa, Toshi A;Geddes, John R
通讯作者：
Geddes, John R
影响因子：
3.3
作者：
Berman, Robert M.;Fava, Maurizio;Marcus, Ronald N.
通讯作者：
Marcus, Ronald N.
影响因子：
17.7
作者：
Bauer, M;Bschor, T;Müller-Oerlinghausen, B
通讯作者：
Müller-Oerlinghausen, B
DOI：
10.1080/10401230490521954
发表时间：
2004-10-01
期刊：
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
影响因子：
--
作者：
Barbee, James G;Conrad, Erich J;Jamhour, Nowal J
通讯作者：
Jamhour, Nowal J